Insmed Inc (INSM)vsVaxcyte Inc (PCVX)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PCVX
Vaxcyte Inc
$55.91
+2.27%
HEALTHCARE · Cap: $7.94B
Smart Verdict
WallStSmart Research — data-driven comparison
PCVX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PCVX
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PCVX
The strongest argument for PCVX centers on Altman Z-Score, Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PCVX
The primary concerns for PCVX are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PCVX is a value play — different risk/reward profiles.
PCVX carries more volatility with a beta of 1.38 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
PCVX generates stronger free cash flow (-230M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Vaxcyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?